Diver C.E.

COMPANY	ev3 Inc.
PHONE	(800) 716-6700
WEB	www.ev3.net

KEY FEATURES

- Rapid exchange, .014-inch guidewire compatible
- Easy set up, 100% disposable
- Low profile and hydrophilic coating for trackability
- Multiple sideholes designed to improve flow and minimize clogging

The Diver C.E. Clot Extraction Catheter from ev3 Inc. (Plymouth, MN) is a new aspiration device available in the US market and cleared for the removal of fresh, soft emboli from arterial vessels in the coronary and peripheral vasculature. The Diver C.E. is manufactured by Invatec s.r.l. (Roncadelle, Italy) and distributed by ev3 as part of their global partnership.

According to the company, the device has several unique characteristics, including sideholes in the distal section that are designed to improve flow and prevent clogging, and an aspiration lumen shaped to maximize suction capacity while delivering the lowest crossing profile available in a 6-F compatible system. In the REMEDIA randomized trial (Burzotta F, et al. *J Am Coll Cardiol*. 2005;46:371-376), the Diver C.E. was shown to significantly improve early reperfusion of coronary vessels in acute myocardial infarction, the company says.

Zenith Renu AAA Ancillary Graft

COMPANY	Cook Incorporated
PHONE	(800) 457-4500
WEB	www.zenithstentgraft.com

KEY FEATURES

- Treats migrating AAA endografts
- Suitable for Dacron and ePTFE membrane endografts
- Two configurations for repairing different endograft designs
- Trigger-wire allows accurate placement with controlled release

The Zenith Renu AAA Ancillary Graft from Cook Incorporated (Bloomington, IN) is designed for secondary endovascular intervention in patients who have undergone previous endovascular repair of infrarenal abdominal aortic aneurysms. The Renu is available in two configurations, a main body extension and a one-piece converter, to accommodate differing endograft designs. The Renu ancillary graft has been engineered to treat migrations in both Dacron and ePTFE membrane-based aortic endografts.

According to the company, Renu utilizes anchoring barbs that provide additional fixation to reduce the risk of further graft migration and to enhance graft-to-vessel sealing. The device uses the same strong, lightweight, shrink-resistant woven synthetic polyester graft material found in all Zenith endografts. The new Renu graft system comes preloaded in Cook's Flexor Introducer System that features a kink-resistant, hydrophilic delivery sheath. A trigger-wire system facilitates accurate placement, controlled release and stabilization of the ancillary endograft during deployment, while the system's Captor Hemostatic Valve inhibits blood reflux, the company says.

Metricath Gemini Catheter

COMPANY	Angiometrx Inc.
PHONE	(866) 760-7131
WEB	www.angiometrx.com

KEY FEATURES

- Combines the Metricath measurement technology with a high-performance angioplasty balloon into a single catheter
- Allows predilation of a lesion and precise measurement of native vessel diameter and area
- Allows postdilation of a stent and confirmation of deployment with the Metricath balloon
- Reduces procedure length by combining two devices into a single catheter

The Metricath Gemini Catheter System from Angiometrx Inc. (Vancouver, BC, Canada) is a low-pressure balloon, catheter-based technology that allows interventionists to precisely measure arterial and stent diameter and cross-sectional area during treatment of arterial disease. According to the company, the Metricath System determines the pressure and volume of fluid within the balloon while it is inflated to a pressure of 250 mm Hg (.33 atm). The system is intended to measure the native artery adjacent to a lesion, or within a stented section of an artery. The size information provided by the Metricath System helps to ensure that the stent size is appropriate for the artery and that full stent expansion has occurred. The Metricath Gemini Balloon Catheter combines a high-performance angioplasty treatment balloon with the Metricath technology, allowing the physician to both measure and dilate a vessel using a single catheter, the company says.

CLiRpath 2.5 Turbo Laser Catheter

COMPANY	Spectranetics Corporation
PHONE	(800) 231-0978
WEB	www.spectranetics.com

KEY FEATURES

- Continuous lasing parameters allow continuous lasing trains without forced stops
- 30% more energy for increased penetration rates
- 30% more active area for improved contact ablation at the catheter tip
- Hydrophilic coating for smooth advancement over the aortic bifurcation

Spectranetics Corporation (Colorado Springs, CO) has launched the CLiRpath 2.5 Turbo Catheter to treat total occlusions in the superficial femoral artery (SFA). The 2.5 Turbo is an addition to the company's CLiRpath line of excimer laser catheters, ranging in diameter from 0.9 mm to 2.5 mm. According to the company, the 2.5 Turbo features several design enhancements, including an increased number of laser fibers, creating 30% more energy and a 60% faster penetration rate to more efficiently ablate larger lumens in the SFA and popliteal arteries; a "continuous on" lasing train, which enables shorter procedure times and reduces radiation exposure; and a hydrophilic coating to allow for smoother advancement through tight lesions and an easier transition over the aortic bifurcation.

"The continuous lasing capability of the CLiRpath 2.5 Turbo catheter allows for easy advancement through long occlusions with more ablation efficiency," said Giancarlo Biamino, MD, PhD, of the Heart Centre Leipzig, in Leipzig Germany. "The recanalization can be performed in less time because you don't need to interrupt the procedure after each laser train. The hydrophilic coating reduces the friction and provides smooth advancement through contralateral sheaths." ■